REGENXBIO INC (RGNX) Stock Price, Quote, News and Overview
NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD
RGNX Quote, Performance and Key Statistics
9.71
-0.15 (-1.52%)
The current stock price of RGNX is 9.71 USD. In the past month the price increased by 6.12%. In the past year, price decreased by -34.92%.
RGNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About RGNX
Company Profile
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Company Info
REGENXBIO INC
9804 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Kenneth T. Mills
Employees: 353
Phone: 12405528181
REGENXBIO INC / RGNX FAQ
What is the stock price of REGENXBIO INC today?
The current stock price of RGNX is 9.71 USD. The price decreased by -1.52% in the last trading session.
What is the ticker symbol for REGENXBIO INC stock?
The exchange symbol of REGENXBIO INC is RGNX and it is listed on the Nasdaq exchange.
On which exchange is RGNX stock listed?
RGNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REGENXBIO INC stock?
18 analysts have analysed RGNX and the average price target is 33.58 USD. This implies a price increase of 245.78% is expected in the next year compared to the current price of 9.71. Check the REGENXBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REGENXBIO INC worth?
REGENXBIO INC (RGNX) has a market capitalization of 487.05M USD. This makes RGNX a Small Cap stock.
How many employees does REGENXBIO INC have?
REGENXBIO INC (RGNX) currently has 353 employees.
What are the support and resistance levels for REGENXBIO INC (RGNX) stock?
REGENXBIO INC (RGNX) has a support level at 8.18 and a resistance level at 9.78. Check the full technical report for a detailed analysis of RGNX support and resistance levels.
Is REGENXBIO INC (RGNX) expected to grow?
The Revenue of REGENXBIO INC (RGNX) is expected to grow by 272.35% in the next year. Check the estimates tab for more information on the RGNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REGENXBIO INC (RGNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RGNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RGNX, evaluating the profitability, health, valuation and growth aspects
- REGENXBIO INC (RGNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REGENXBIO INC (RGNX) Sales and EPS estimates to see what analysts future expectations are.
- REGENXBIO INC (RGNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REGENXBIO INC (RGNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- REGENXBIO INC (RGNX) Stock Chart to make your own analysis
- REGENXBIO INC (RGNX) Latest news and press-releases to stay up to date.
Does REGENXBIO INC (RGNX) stock pay dividends?
RGNX does not pay a dividend.
When does REGENXBIO INC (RGNX) report earnings?
REGENXBIO INC (RGNX) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of REGENXBIO INC (RGNX)?
REGENXBIO INC (RGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.11).
What is the Short Interest ratio of REGENXBIO INC (RGNX) stock?
The outstanding short interest for REGENXBIO INC (RGNX) is 11.16% of its float. Check the ownership tab for more information on the RGNX short interest.
RGNX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RGNX. When comparing the yearly performance of all stocks, RGNX turns out to be only a medium performer in the overall market: it outperformed 50.24% of all stocks.
RGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RGNX. While RGNX seems to be doing ok healthwise, there are quite some concerns on its profitability.
RGNX Financial Highlights
Over the last trailing twelve months RGNX reported a non-GAAP Earnings per Share(EPS) of -3.11. The EPS increased by 46.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.12% | ||
| ROE | -57.51% | ||
| Debt/Equity | 0 |
RGNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to RGNX. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 87.55% and a revenue growth 272.35% for RGNX